Company
Every investor coverage indicates participated in a round Merck raised.
Companies Merck acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| David Peacock | Global Vaccines President (former) | OneVentures portfolio (Fri 17 Apr 2026), OneVentures portfolio (Mon 12 Jan 2026), OneVentures portfolio (Thu 9 Oct 2025), OneVentures portfolio (Wed 9 Oct 2024), OneVentures portfolio (Tue 13 Feb 2024), OneVentures portfolio (Tue 12 Dec 2023), OneVentures portfolio (Tue 6 Dec 2022) |
| Ken Frazier | Chairman and Chief Executive Officer | Beef Central / Grain Central |
| Rick DeLuca | President | Beef Central / Grain Central |
| Stefan König | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Merck. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A fund's insights listing: its headline flags Vaxxas naming an ex-Merck vaccines chief as CEO, while linked teasers report Eucalyptus' $1.6b sale and Accel-KKR's takeover of Phocas.
Also OneVentures portfolio·AFR Technology·phocassoftware.com
Curated OneVentures roundup: Eucalyptus sold to a New York-listed healthcare group for $1.6 billion and Vaxxas named ex-Merck vaccines president David Peacock as CEO, plus patent-cliff and women-in-tech links.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
OneVentures' insights feed highlights a pharma patent-cliff analysis, an AFR feature, Eucalyptus' $1.6b sale to a US healthcare group, and Vaxxas naming David Peacock chief executive.
Manufacturing roundup: Australian Vanadium and entX land government grants, Hexagon Energy Materials completes a $1 million round, Australian Dairy Nutritionals appoints a CEO, Aurora Labs adds a director, plus vessel, export and research briefs.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
OneVentures insights listing linking to coverage of Eucalyptus's $1.6b sale to a US-listed healthcare company and Vaxxas hiring a former Merck vaccines president as CEO.
Publisher's post about a venture firm multiplying its money thirteen-fold on one startup bet; the page also carries linked reports of Eucalyptus's $1.6 billion sale and Vaxxas naming David Peacock chief executive.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia
Weekly roundup covering six startup raises: ImmVirX, Nutromics, Nuheara, Autism 360, Cogo and Gather, plus Nutromics' 30X30 selection, a board appointment and Viralytics' earlier sale to Merck.
Two Perth startups have each secured $3 million. GeoMoby drew mostly French backers plus Agreement Hub and a METS Ignited grant; Vedi raised mainly from MSD Animal Health, with Companion Fund also taking part.
Perth veterinary tech startup Vedi raised $3 million from MSD Animal Health and New York's Companion Fund to expand its pet medical record platform in Australia and the UK.
A OneVentures post reports a needle-free vaccine developer raising A$34 million; linked items on the page note Eucalyptus's $1.6 billion sale to a US-listed healthcare firm and Vaxxas naming David Peacock chief executive.
Also Blackbird Ventures portfolio·Startup Daily·SmartCompany·Dealroom·SmartCompany·Startup Daily·AFR Technology·Dealroom·Forbes Australia
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.
Wrap-up of conference sessions in Darwin on consumer data, ESG lending and provenance trends for cattle businesses, noting US virtual-fencing startup Vence securing corporate backing from Shell and Merck.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.
Biotech firm Aravax has added Thomas Ulmer, previously CFO at Immatics and Allergopharma with Merck roles, to its board as its peanut allergy treatment advances after positive phase 1 safety results.
Roundup of manufacturing sector items: a medtech firm completes a capital raising, a biotech receives a government tax refund, two cannabis suppliers record export sales, and a diagnostics maker ships machines to a German laboratory group.
Vaxxas has received a US$22 million (A$30.6 million) US government BARDA award to advance its needle-free vaccine patch for pandemic use; earlier financing led by OneVentures with Brandon Capital is recalled.
Biotech Vaxxas has won a US government award via BARDA worth US$22 million to advance its needle-free vaccine patch for pandemic influenza; the piece recalls founding backing from OneVentures, Brandon Capital, MRCF and HealthCare Ventures.
Blade Therapeutics appoints Mark Timney as board chairman, succeeding co-founder Luke Evnin; the release recalls its roughly $90 million raised from investors including OneVentures and The Medicines Company's $9.7 billion sale to Novartis.
Profile of Brisbane medtech firm Vaxxas on scaling its needle-free vaccine patch from prototype toward commercial manufacture, with pharma partner Merck and production specialist Harro Hofliger announced as collaborators.
Vaxxas completed a $25 million Series B led by OneVentures, lifting total capital to $40 million, to advance its needle-free Nanopatch vaccine delivery technology toward first clinical studies.